You are on page 1of 2

Corporate

Office : Mahendra Industrial Estate,


------'
PIot No. 109-D, Road No. 29,
Sion (East).
\----t'
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 24OI gO2S (30
Lines)
Fax:022-2407 3462 / 2407 0t44 - -"'--'

'

- -

Aarti Drugs Limited


Manufacturers

aa

Email : admin@aartidrugs.com
Website ; www.aartidruqs.com

of : aulk Orugs & Chemicals

crN NO : 137060MH1d'e+plcoss+::

Ref.: ADI,/Sry2f[:6-tz
Date: L2rh Augus t, 201.6
To,
Department of Corporate Service,
BSE Ltd.
Phiroze |eejeebhoy Towers,
Dalal Street, Mumbai _ 400 001.
BSE CODE - 524348

To,

National Stock Exchange of India


Limited,
"Exchange p)laza,,, Bandra _ Kurla
Complex,
Bandra (E), Mtumbai - 400051.

Sub: Press Release


Dear Sir/Madam,

find encrosed herewith copy of the press


release issued by the Company
on 12ft
August,2016.
Piease

This is for your kind information


and records. Kindry acknLowledge
the receipt.

Thanking you,
Yours faithfully,
For Aarti Drugs Limited

{,3
viur',;frilil
Company Secretary & Compliance

ffiD

Officer
.

Encl:

A/A

S;oN

Regd' officc : prot No. N-1g8, MIDC, Tarapur,


Tar-parghar, Dist. parghar - 401 506. (MH)

t-

Corporate Office : Mahendra Industrial Estate,

=t

Aarti Drugs Limited


Manufacturers of : Butk Drugs & Chemicats

Plot No. 109-D, Road No. 29, Sion (East),


Mumbai - 400 022. (India)
Tel.: 022-24O7 2249 / 24CIL 9OZ5 (30 Lines)
Fax:022-2407 3462 | 2407 0t44
Email : admin@aartidrugs.com
Website : www.aaftidrugs.com

CIN NO : 137060MH1984p1C055433

Press Release

Press release for lun,16:

Domestic market share for the key products has grown significantly over same
quarter
gf the previous year. Due to falling crude pricei, raw material and consequenfly the

finished goods selling prices havs shown u do*n*ard trend. This has led to raw
material inventory loss, adversely affecting the bottom-line, but it was partially
,
mitigated by the increased market rhur" to the extent of 17.21.% across its products.

Consolidated Profit after tax for the quarter ended


Jun'16 is 19.94crores, up by 14.64%

due to strong operational performance and reduction in overall interest cost.


Consolidated EBITDA for the quarter ended Jun'16 is 48.14 crores, up by g.g4%.
Company was able to keep its working capital cycle to optimum and further reduced
the Debt/Equity ratio.

Expanded capacities from the last year's expansion program have contributed
to
increased sales, which is evident in the number of units sold. Company
recently replied
to USFDA's request for information and is further upgrading its quailty systems,
with
the help of USFDA consultants.
Fol Aarti Drugs Limited
il

ud*#
Harshit M. Savla
Jt. Managing Director
DIN:00005340

Regd. Office : Plot No. N-19g, MIDC, Tarapur, Tal-palghar, Dist. Palghar 401 s06. (MH)

You might also like